Join the NPC evidence-based therapeutics team as they discuss some important recent studies and therapeutic news. This month:
- No significant benefits for early detection and intensive multifactorial management of type 2 diabetes
- SHARP RCT shows ezetimibe/simvastatin reduces CV events in CKD: but is it better than simvastatin alone?
- New safety information for pioglitazone▼, dronedarone▼, varenicline▼, and Pandemrix®▼
Please click on the hyperlink above to access the Rapid Review on this topic
The podcast lasts 13:34 minutes.
|Subscribe to the NPC podcast via the iTunes store|
|Subscribe to the NPC podcast via RSS feed|